Skip to main content
Oxford Research Peptides
MECHANISM NOTE

GLP-1 Receptor Explained

A concise reference on the glucagon-like peptide-1 receptor — its classification, signalling and role as a research target for the incretin-mimetic peptide family.

QUICK ANSWER
TL;DR

Quick answer

The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor activated by the endogenous incretin hormone glucagon-like peptide-1 (7-36). It signals primarily via Gαs / cAMP and is the shared target of a large family of research peptides, from single-agonist analogues to Retatrutide's triple-agonist scaffold.
EXTENDED ANSWER
AI-ready

Extended answer

What is the GLP-1 receptor and why does it matter for research peptides?

The GLP-1 receptor (GLP-1R) is a class B secretin-like G-protein-coupled receptor activated by the endogenous incretin hormone glucagon-like peptide-1 (7-36) amide. Ligand binding at its large extracellular N-terminal domain stabilises an active conformation that engages Gαs, elevates cyclic AMP and activates downstream effectors including protein kinase A and Epac. In the pancreas, GLP-1R signalling amplifies glucose-dependent insulin secretion; in the central nervous system it contributes to satiety signalling. GLP-1R is the shared molecular target of a large family of research peptides: single-agonists such as Semaglutide engage GLP-1R alone, dual-agonists such as Tirzepatide add GIPR, and triple-agonists such as Retatrutide add GCGR to the same scaffold. Working with recombinant human GLP-1R in HEK293 or CHO cell lines supports cAMP-based functional assays.
KEY FACTS

Key facts

Receptor class
Class B GPCR (secretin-like)
Endogenous ligand
GLP-1 (7-36) amide
Primary coupling
Gαs / cAMP
Research family
Incretin mimetics

Definition · Incretin

Gut-derived peptide hormones — principally GLP-1 and GIP — that potentiate glucose-dependent insulin secretion after nutrient intake.

Classification

GLP-1R belongs to the class B (secretin-like) family of seven- transmembrane G-protein-coupled receptors. Class B GPCRs are characterised by a large extracellular N-terminal domain that binds peptide ligands and stabilises the active receptor conformation.[6]

Endogenous ligand and signalling

The endogenous ligand at GLP-1R is glucagon-like peptide-1 (7-36) amide, released from intestinal L-cells in response to nutrient ingestion.[4] Activation of GLP-1R engages Gαs, elevates intracellular cyclic AMP and activates downstream effectors including protein kinase A and Epac.[5]

Why it matters for research peptides

GLP-1R is the shared receptor target for a wide range of research peptides. Some are single-agonist analogues (for example, Semaglutide and Liraglutide sequences), while others engage additional receptors — Tirzepatide adds GIPR, and Retatrutide adds both GIPR and GCGR to its GLP-1R activity.[1]

Working with GLP-1R in vitro

Recombinant human GLP-1R expressed in HEK293 or CHO cell lines is a common substrate for functional cAMP assays. When comparing potency values across publications, note the receptor construct, tag and readout technology — small differences in assay design can shift absolute potency measurements.

Related pathway concepts

  • The incretin effect — the observation that oral glucose elicits a larger insulin response than intravenous glucose at matched glycaemia.[4]
  • Class B GPCR pharmacology — extracellular-domain-driven ligand recognition and Gαs-dominant coupling.[6]

References6

  1. 1.

    Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metabolism. 2022;34(9):1234-1247.

    DOI: 10.1016/j.cmet.2022.07.013PMID: 35985340
  2. 2.

    Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.

    DOI: 10.1056/NEJMoa2301972PMID: 37366315
  3. 3.

    Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.. The Lancet. 2023;402(10401):529-544.

    DOI: 10.1016/S0140-6736(23)01053-XPMID: 37385275
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  6. 6.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors: a long march to therapeutic successes.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
GLP-1R is a well-characterised receptor with extensive independent literature spanning pharmacology, structural biology and clinical research.
RELATED GUIDES
COMPOUNDS TARGETING GLP-1R
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-07-15
Updated
2026-07-15
Reviewed
2026-07-15
Version
1.0

Revision history

  1. v1.02026-07-15· Editorial Team

    Initial publication as part of the Retatrutide authority cluster (Release 4.0).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-01-15. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-07-15Updated: 2026-07-15